{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05519449",
            "orgStudyIdInfo": {
                "id": "PSMA-007-001"
            },
            "secondaryIdInfos": [
                {
                    "id": "ENGAGER-PSMA-01",
                    "type": "OTHER",
                    "domain": "Janux Therapeutics., Inc"
                }
            ],
            "organization": {
                "fullName": "Janux Therapeutics",
                "class": "INDUSTRY"
            },
            "briefTitle": "Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)",
            "officialTitle": "A Phase 1, Open-Label, Multicenter Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "study-of-in-subjects-with-metastatic-castration-resistant-prostate-cancer-engager-psma"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-03",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2022-09-15",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-08",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-03",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-08-25",
            "studyFirstSubmitQcDate": "2022-08-25",
            "studyFirstPostDateStruct": {
                "date": "2022-08-29",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-02-29",
            "lastUpdatePostDateStruct": {
                "date": "2024-03-04",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Janux Therapeutics",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This study is a first-in-human, Phase 1, open-label, multicenter study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and the preliminary efficacy of JANX007 administered as a single agent in adults with metastatic castration-resistant prostate cancer (mCRPC)."
        },
        "conditionsModule": {
            "conditions": [
                "Prostate Cancer",
                "Metastatic Castration-resistant Prostate Cancer",
                "Castration Resistant Prostatic Cancer"
            ],
            "keywords": [
                "Prostate Cancer",
                "Castration-resistant prostate cancer"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 105,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Dose Escalation",
                    "type": "EXPERIMENTAL",
                    "description": "IV dosing during 21- or 28-day cycles. Dosage per cohort will increase to determine the maximum tolerable dose.",
                    "interventionNames": [
                        "Biological: JANX007"
                    ]
                },
                {
                    "label": "Backfill Expansion",
                    "type": "EXPERIMENTAL",
                    "description": "IV dosing during 21- or 28-day cycles. Subjects will be dosed at levels previously declared tolerable.",
                    "interventionNames": [
                        "Biological: JANX007"
                    ]
                },
                {
                    "label": "Expansion",
                    "type": "EXPERIMENTAL",
                    "description": "IV dosing during 21- or 28-day cycles. Subjects will be dosed at preliminary recommended phase 2 dose (RP2D).",
                    "interventionNames": [
                        "Biological: JANX007"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "BIOLOGICAL",
                    "name": "JANX007",
                    "description": "JANX007 is dosed via IV in a 21- or 28-day cycle.",
                    "armGroupLabels": [
                        "Backfill Expansion",
                        "Dose Escalation",
                        "Expansion"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Incidence of Dose Limiting Toxicities (DLT)",
                    "timeFrame": "3 years"
                },
                {
                    "measure": "Incidence of Adverse Events (AE) and Serious Adverse Events (SAE)",
                    "timeFrame": "3 years"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Area under the concentration time curve to infinity of JANX007 (AUC0-inf)",
                    "timeFrame": "Pre-dose and at multiple timepoints post-dose on Days 1, 2, 4, 8, 9, 15, 16, 18 up to end of treatment (Up to 3 years)"
                },
                {
                    "measure": "Maximum observed concentration of JANX007 (Cmax)",
                    "timeFrame": "Pre-dose and at multiple timepoints post-dose on Days 1, 2, 4, 8, 9, 15, 16, 18 up to end of treatment (Up to 3 years)"
                },
                {
                    "measure": "Number of participants who develop anti-drug antibodies against JANX007",
                    "timeFrame": "Up to 3 years"
                },
                {
                    "measure": "Duration of Response",
                    "description": "Time from documentation of complete response or partial response to disease progression using RECIST v1.1 and PCWG3",
                    "timeFrame": "Up to 3 years"
                },
                {
                    "measure": "Prostate Specific Antigen (PSA) response",
                    "description": "Best reduction in PSA level achieved",
                    "timeFrame": "Up to 3 years"
                },
                {
                    "measure": "Radiographic Progression Free Survival (rPFS)",
                    "description": "Time from treatment initiation to radiographic evidence of disease progression using RECIST v1.1 and PCWG3",
                    "timeFrame": "Up to 3 years"
                },
                {
                    "measure": "Overall Response Rate",
                    "description": "Proportion of participants who achieve a complete response or partial response using RECIST v1.1 and PCWG3",
                    "timeFrame": "Up to 3 years"
                },
                {
                    "measure": "Overall Survival",
                    "description": "Time from treatment initiation until death from any cause",
                    "timeFrame": "Up to 3 years"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Male \u226518 years of age at the time of signing informed consent\n* Histologically or cytologically confirmed adenocarcinoma of the prostate\n* Having mCRPC that progressed after at least one novel anti-androgen therapy and at least one taxane containing regimen. Participants who have actively refused a taxane containing regimen or are medically unsuitable to receive taxane are eligible\n* Adequate organ function\n\nExclusion Criteria:\n\n* Prior solid organ transplant\n* Prior treatment with PSMA-targeted CAR-T cell therapy or PSMA-CD3, PSMA-CD28 or other CD3 T-cell engaging bispecific antibodies\n* Clinically significant cardiovascular disease\n* Active clinically significant infection (bacterial, viral, fungal, mycobacteria or other)\n* Any medical condition or clinical laboratory abnormality likely to interfere with assessment of safety or efficacy of study treatment",
            "healthyVolunteers": false,
            "sex": "MALE",
            "genderBased": true,
            "genderDescription": "Gender Identity",
            "minimumAge": "18 Years",
            "maximumAge": "100 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Janux Therapeutics",
                    "role": "CONTACT",
                    "phone": "858-751-4493",
                    "email": "psma-007-001_ct.gov@januxrx.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Janux Therapeutics, MD",
                    "affiliation": "Janux Therapeutics",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "UCLA Department of Medicine - Hematology/Oncology",
                    "status": "RECRUITING",
                    "city": "Los Angeles",
                    "state": "California",
                    "zip": "90095",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 34.05223,
                        "lon": -118.24368
                    }
                },
                {
                    "facility": "UCSF Helen Diller Family Comprehensive Cancer Center",
                    "status": "RECRUITING",
                    "city": "San Francisco",
                    "state": "California",
                    "zip": "94158",
                    "country": "United States",
                    "contacts": [
                        {
                            "role": "CONTACT",
                            "email": "HDFCCC.CIP@ucsf.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 37.77493,
                        "lon": -122.41942
                    }
                },
                {
                    "facility": "Yale New Haven Hospital",
                    "status": "RECRUITING",
                    "city": "New Haven",
                    "state": "Connecticut",
                    "zip": "06510",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 41.30815,
                        "lon": -72.92816
                    }
                },
                {
                    "facility": "Washington University School of Medicine",
                    "status": "RECRUITING",
                    "city": "Saint Louis",
                    "state": "Missouri",
                    "zip": "63110",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 38.62727,
                        "lon": -90.19789
                    }
                },
                {
                    "facility": "Memorial Sloan Kettering Cancer Center",
                    "status": "ACTIVE_NOT_RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10065",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "Oregon Health and Science University",
                    "status": "RECRUITING",
                    "city": "Portland",
                    "state": "Oregon",
                    "zip": "97239",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 45.52345,
                        "lon": -122.67621
                    }
                },
                {
                    "facility": "Sarah Cannon Research",
                    "status": "RECRUITING",
                    "city": "Nashville",
                    "state": "Tennessee",
                    "zip": "37203",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 36.16589,
                        "lon": -86.78444
                    }
                },
                {
                    "facility": "Mary Crowley Cancer Research",
                    "status": "RECRUITING",
                    "city": "Dallas",
                    "state": "Texas",
                    "zip": "75230",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 32.78306,
                        "lon": -96.80667
                    }
                },
                {
                    "facility": "Chris O'Brien Lifehouse (COBLH)",
                    "status": "RECRUITING",
                    "city": "Camperdown",
                    "state": "New South Wales",
                    "zip": "2050",
                    "country": "Australia",
                    "geoPoint": {
                        "lat": -33.88965,
                        "lon": 151.17642
                    }
                },
                {
                    "facility": "Southern Oncology Clinical Research Unit (SoCRU)",
                    "status": "RECRUITING",
                    "city": "Bedford Park",
                    "state": "South Australia",
                    "zip": "5042",
                    "country": "Australia",
                    "geoPoint": {
                        "lat": -35.03333,
                        "lon": 138.56667
                    }
                },
                {
                    "facility": "Linear Clinical Research Ltd.",
                    "status": "RECRUITING",
                    "city": "Nedlands",
                    "state": "Western Australia",
                    "zip": "6009",
                    "country": "Australia",
                    "geoPoint": {
                        "lat": -31.98184,
                        "lon": 115.8073
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000011471",
                    "term": "Prostatic Neoplasms"
                },
                {
                    "id": "D000064129",
                    "term": "Prostatic Neoplasms, Castration-Resistant"
                }
            ],
            "ancestors": [
                {
                    "id": "D000005834",
                    "term": "Genital Neoplasms, Male"
                },
                {
                    "id": "D000014565",
                    "term": "Urogenital Neoplasms"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000005832",
                    "term": "Genital Diseases, Male"
                },
                {
                    "id": "D000091662",
                    "term": "Genital Diseases"
                },
                {
                    "id": "D000091642",
                    "term": "Urogenital Diseases"
                },
                {
                    "id": "D000011469",
                    "term": "Prostatic Diseases"
                },
                {
                    "id": "D000052801",
                    "term": "Male Urogenital Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M14335",
                    "name": "Prostatic Neoplasms",
                    "asFound": "Prostate Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M30215",
                    "name": "Prostatic Neoplasms, Castration-Resistant",
                    "asFound": "Castration-Resistant Prostatic Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M8946",
                    "name": "Genital Neoplasms, Male",
                    "relevance": "LOW"
                },
                {
                    "id": "M17315",
                    "name": "Urogenital Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M2876",
                    "name": "Genital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M8944",
                    "name": "Genital Diseases, Male",
                    "relevance": "LOW"
                },
                {
                    "id": "M2875",
                    "name": "Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14333",
                    "name": "Prostatic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M27095",
                    "name": "Male Urogenital Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BXS",
                    "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        }
    },
    "hasResults": false
}